Targeting gut microbiota and metabolites in cancer radiotherapy

Abstract

Radiotherapy (RT) is a cornerstone in cancer treatment, but often causes radiation-induced injury. Accumulating evidence points to the gut microbiota in modulating immune functions and maintaining intestinal integrity to impact RT efficacy. This review examines the current understanding of intestinal flora and their metabolites within the context of RT. We outlined the current research applications in how microbiota-targeted strategies such as probiotics, prebiotics, dietary interventions, and faecal microbiota transplantation could restore microbial balance, reduce toxicity, and improve patient prognosis. Microbial byproducts such as short-chain fatty acids, bile acids and tryptophan exhibit protective effects against radiation damage, supporting immune modulation and enhancing tumour radiosensitivity. These microbial products underscore the potential of gut microbiota-targeted therapies as adjunctive treatments in RT, with implications for reducing toxicity and personalizing cancer care. All these strategies targeting gut microbiota and metabolites potentially aim to develop innovative therapies that boost RT effectiveness while minimizing side effects, and finally revolutionizing personalized cancer treatment.

Keywords

cancer / gut microbiota and metabolites / radiotherapy

References

[1] Siegel R, Giaquinto A, Jemal A. Cancer statistics, 2024. CA: Cancer J Clin. 2024; 74: 12–49.

[2] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2024; 74(3): 229–263.

[3] Singh AK, Vijay A, and Bhushan M, Dosimetric assessment of conventional and advanced algorithms in clinical stereotactic radiotherapy. Precision Radiation Oncology, 2025.

[4] Chen Z, Yan X, Xie S, et al. Exploring the potential benefits of multi-field IMPT for stage I NSCLC SBRT: An in silico dosimetric comparison to IMRT and CyberKnife. Precision Radiation Oncology, 2025.

[5] Cytlak U, Dyer DP, Honeychurch J, Williams KJ, Travis MA, Illidge TM. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat Rev Immunol. 2022; 22(2): 124–138.

[6] Vozenin M, Bourhis J, Durante M. Towards clinical translation of FLASH radiotherapy. Nat Rev Clin Oncol. 2022; 19(12): 791–803.

[7] Byun H, Kim C, Seong J. Carbon ion radiotherapy in the treatment of hepatocellular carcinoma. Clin Mol Hepatol. 2023; 29(4): 945.

[8] Wu Y, Song Y, Wang R, Wang T. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023; 22(1): 96.

[9] Wang Z, Ren X, Li Y, et al. Reactive oxygen species amplifier for apoptosis-ferroptosis mediated high-efficiency radiosensitization of tumors. ACS Nano. 2024; 18(14): 10288–10301.

[10] Galluzzi L, Aryankalayil MJ, Coleman CN, Formenti SC. Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023; 20(8): 543–557.

[11] Dasgupta Q, Jiang A, Wen AM, et al. A human lung alveolus-on-a-chip model of acute radiation-induced lung injury. Nat Commun. 2023; 14(1): 6506.

[12] Nolan E, Bridgeman VL, Ombrato L, et al. Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization. Nat Cancer. 2022; 3(2): 173–187.

[13] Wang K, Tepper J. Radiation therapy-associated toxicity: etiology, management, and prevention. CA: Cancer J Clin. 2021; 71(5): 437–454.

[14] Anderson N, Simon M. The tumor microenvironment. Curr Biol. 2020; 30(16): R921–R925.

[15] White M, Sears C. The microbial landscape of colorectal cancer. Nat Rev Microbiol. 2024; 22(4): 240–254.

[16] Margolis K, Cryan J, Mayer E. The microbiota-gut-brain axis: from motility to mood. Gastroenterology. 2021; 160(5): 1486–1501.

[17] Moraitis I, Guiu J, Rubert J. Gut microbiota controlling radiation-induced enteritis and intestinal regeneration. Trends Endocrinol Metab. 2023; 34(8): 489–501.

[18] Takeuchi T, Nakanishi Y, Ohno H. Microbial metabolites and gut immunology. Ann Rev Immunol. 2024; 42(1): 153–178.

[19] Blake S, Wolf Y, Boursi B, Lynn DJ, et al. Role of the microbiota in response to and recovery from cancer therapy. Nat Rev Immunol. 2024; 24(5): 308–325.

[20] Li X, Mo Y, Shang S, et al. Gut Escherichia coli promotes lung cancer by increasing circulating STAMBP production. Discover Oncol. 2025; 16(1): 459.

[21] Goenka A, Khan F, Verma B, et al. Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Commun. 2023; 43(5): 525–561.

[22] Yang Q, Wang B, Zheng Q, et al. A review of gut microbiota-derived metabolites in tumor progression and cancer therapy. Adv Sci. 2023; 10(15): e2207366.

[23] Yang Q, Wang B, Zheng Q, et al. A Review of gut microbiota-derived metabolites in tumor progression and cancer therapy. Adv Sci (Weinh). 2023; 10(15): e2207366.

[24] Jassim A, Rahrmann EP, Simons BD, Gilbertson RJ. Cancers make their own luck: theories of cancer origins. Nat Rev Cancer. 2023; 23(10): 710–724.

[25] Stolte M, et al. Helicobacter and gastric MALT lymphoma. Gut. 2002; 50(3): III19–24.

[26] Shukla R, Shukla P, Behari A, et al. Roles of Salmonella typhi and Salmonella paratyphi in gallbladder cancer development. Asian Pacific J Cancer Prevent. 2021; 22(2): 509.

[27] Zafar H, Saier Jr M. Gut Bacteroides species in health and disease. Gut Microbes. 2021; 13(1): 1848158.

[28] Zhang X, Yu D, Wu D, et al. Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance. Cell Host Microbe. 2023; 31(3): 418-432. e8.

[29] Wang N, Fang J. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. Trends Microbiol. 2023; 31(2): 159–172.

[30] Drewes J, Chen J, Markham NO, et al. Human Colon Cancer-Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice. Cancer Discov. 2022; 12(8): 1873–1885.

[31] Zagato E, Pozzi C, Bertocchi A, et al. Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nat Microbiol. 2020; 5(3): 511–524.

[32] Chen S, Zhang L, Li M, et al. Fusobacterium nucleatum reduces METTL3-mediated m6A modification and contributes to colorectal cancer metastasis. Nat Commun. 2022; 13(1): 1248.

[33] Ternes D, Tsenkova M, Pozdeev VI, et al. The gut microbial metabolite formate exacerbates colorectal cancer progression. Nat Metab. 2022; 4(4): 458–475.

[34] Fu A, Yao B, Dong T, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell. 2022; 185(8): 1356-1372. e26.

[35] Bell H, Rebernick RJ, Goyert J, et al. Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance. Cancer Cell. 2022; 40(2): 185-200. e6.

[36] Han J, Tao Z, Wang J, et al. Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on colorectal cancer. Nat Microbiol. 2023; 8(5): 919–933.

[37] Belkaid Y, Hand T. Role of the microbiota in immunity and inflammation. Cell. 2014; 157(1): 121–141.

[38] Fernandes A, Oliveira A, Guedes C, Fernandes R, Soares R, Barata P. Ionizing radiation from radiopharmaceuticals and the human gut microbiota: an ex vivo approach. Int J Mol Sci. 2022; 23(18): 10809.

[39] Guo H, Chou W, Lai Y, et al. Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites. Science. 2020; 370(6516): eaay9097.

[40] Ruan J, Lee C, Wouters S, et al. Irradiation at ultra-high (FLASH) dose rates reduces acute normal tissue toxicity in the mouse gastrointestinal system. Int J Radiat Oncol Biol Phys. 2021; 111(5): 1250–1261.

[41] Zhao T, Xie L, Cai S, et al. Dysbiosis of gut microbiota is associated with the progression of radiation-induced intestinal injury and is alleviated by oral compound probiotics in mouse model. Front Cell Infect Microbiol. 2021; 11: 717636.

[42] Wang X, Guo L, Qin T, et al. Effects of X-ray cranial irradiation on metabolomics and intestinal flora in mice. Ecotoxicol Environ Saf. 2024; 270: 115898.

[43] Zhang L, Xu J, Xing Y, et al. Lactobacillus rhamnosus GG alleviates radiation-induced intestinal injury by modulating intestinal immunity and remodeling gut microbiota. Microbiol Res. 2024; 286: 127821.

[44] Kalkeri R, Walters K, Van Der Pol W, et al. Changes in the gut microbiome community of nonhuman primates following radiation injury. BMC Microbiol. 2021; 21: 1–10.

[45] Patel R, Ye M, Carlson PM, et al. Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles. Adv Mater. 2019; 31(43): 1902626.

[46] Khil M, Kim JH, Mullen CA, Kim SH, Freytag SO. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res. 1996; 2(1): 53–57.

[47] Shiao S, Kershaw KM, Limon JJ, et al. Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. Cancer cell. 2021; 39(9): 1202-1213. e6.

[48] Dong J, Wang B, Xiao Y, et al. Roseburia intestinalis sensitizes colorectal cancer to radiotherapy through the butyrate/OR51E1/RALB axis. Cell Reports. 2024; 43(3).

[49] Yang J, Wu Z, Chen Y, et al. Pre-treatment with Bifidobacterium infantis and its specific antibodies enhance targeted radiosensitization in a murine model for lung cancer. J Cancer Res Clin Oncol. 2021; 147: 411–422.

[50] Park M, Kwon J, Shin H, et al. Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patient-derived organoids. Int J Oncol. 2020; 57(6): 1307–1318.

[51] Yang K, Hou Y, Zhang Y, et al. Suppression of local type I interferon by gut microbiota–derived butyrate impairs antitumor effects of ionizing radiation. Journal of Experimental Medicine. 2021; 218(3): e20201915.

[52] Then C, Paillas S, Wang X, Hampson A, Kiltie AE. Radiosensitisation of bladder cancer cells via short-chain fatty acids and/or other metabolites produced by the gut microbiota. Urologic oncology: seminars and original investigations. Elsevier; 2020.

[53] Dong J, Li Y, Xiao H, et al. Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models. Cell Reports. 2021; 37(4).

[54] Shi W, Shen L, Zou W, et al. The gut microbiome is associated with therapeutic responses and toxicities of neoadjuvant chemoradiotherapy in rectal cancer patients—a pilot study. Front Cell Infect Microbiol. 2020; 10: 562463.

[55] Yi Y, Shen L, Xia F, et al. The gut microbiome profile predicts the severe acute toxicities in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys. 2021; 111(3): S103–S104.

[56] McCurry E. Assessment of intestinal microbiome features as predictive biomarkers of radiation-induced lung injury. University of British Columbia; 2024.

[57] Reis Ferreira M, Andreyev HJN, Mohammed K, et al. Microbiota-and radiotherapy-induced gastrointestinal side-effects (MARS) study: a large pilot study of the microbiome in acute and late-radiation enteropathy. Clin Cancer Res. 2019; 25(21): 6487–6500.

[58] Wang A, Ling Z, Yang Z, et al. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PloS One. 2015; 10(5): e0126312.

[59] Chen Z, Xiao H, Dong JL, et al. Gut microbiota-derived PGF2α fights against radiation-induced lung toxicity through the MAPK/NF-κB pathway. Antioxidants (Basel). 2021; 11(1): 65.

[60] Thandar M, Yang X, Zhu Y, et al. Dysbiosis of gut microbiota and metabolites is associated with radiation-induced colorectal fibrosis and is restored by adipose-derived mesenchymal stem cell therapy. Life Sci. 2024; 341: 122502.

[61] Chen Z, Xiao HW, Dong JL, et al. Gut Microbiota-Derived PGF2alpha Fights against Radiation-Induced Lung Toxicity through the MAPK/NF-kappaB Pathway. Antioxidants (Basel). 2021; 11(1): 65.

[62] Li Y, Sui L, Zhao H, et al. Differences in the establishment of gut microbiota and metabolome characteristics between BALB/c and C57BL/6J mice after proton irradiation. Front Microbiol. 2022; 13: 874702.

[63] Lin M, Wu Y, Yang J, et al. Gut microbiota characteristics are associated with severity of acute radiation-induced esophagitis. Front Microbiol. 2022; 13: 883650.

[64] Qiu B, Xi Y, Liu F, et al. Gut microbiome is associated with the response to chemoradiotherapy in patients with non-small cell lung cancer. Int J Radiat Oncol Biol. Phys. 2023; 115(2): 407–418.

[65] Eaton S, Kaczmarek J, Mahmood D, et al. Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients. Brit J Cancer. 2022; 127(12): 2087–2098.

[66] Yi Y, Shen L, Shi W, et al. Gut microbiome components predict response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a prospective, longitudinal study. Clin Cancer Res. 2021; 27(5): 1329–1340.

[67] Kumagai T, Rahman F, Smith A. The microbiome and radiation induced-bowel injury: evidence for potential mechanistic role in disease pathogenesis. Nutrients. 2018; 10(10).

[68] Jameus A, Dougherty J, Narendrula R, et al. Acute impacts of ionizing radiation exposure on the gastrointestinal tract and gut microbiome in mice. Int J Mol Sci. 2024; 25(6): 3339.

[69] Xu M, Qiu X, Chen Q, et al. Changes of gut microbiome and metabolome in the AOM/DSS mouse model of colorectal cancer with FLASH radiation. Radiat Med Protect. 2023; 4(1): 1–10.

[70] Mann E, Lam Y, Uhlig H. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. 2024: 1–19.

[71] Guo L, Da F, Gao Q, et al. Irradiation-induced intestinal injury is associated with disorders of bile acids metabolism. Int J Radiat Oncol Biol Phys. 2023; 115(2): 490–500.

[72] Collins S, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023; 21(4): 236–247.

[73] Fuchs C, Trauner M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol. 2022; 19(7): 432–450.

[74] Cai J, Sun L, Gonzalez F. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. Cell Host Microbe. 2022; 30(3): 289–300.

[75] Chandra R, Keane FK, Voncken FEM, Thomas CR. Contemporary radiotherapy: present and future. Lancet. 2021; 398(10295): 171–184.

[76] Sánchez-Alcoholado L, Laborda-Illanes A, Otero A, et al. Relationships of gut microbiota composition, short-chain fatty acids and polyamines with the pathological response to neoadjuvant radiochemotherapy in colorectal cancer patients. Int J Mol Sci. 2021; 22(17): 9549.

[77] Li Z, Zhang Y, Hong W, et al. Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling. Gut Microbes. 2022; 14(1): 2119055.

[78] Xu C, Chen L, Liu G, et al. Tailoring an intravenously injectable oncolytic virus for augmenting radiotherapy. Cell Rep Med. 2025; 6(5).

[79] Fusco W, Lorenzo MB, Cintoni M, et al. Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients. 2023; 15(9): 2211.

[80] Meldrum O, Yakubov G. Journey of dietary fiber along the gastrointestinal tract: role of physical interactions, mucus, and biochemical transformations. Crit Rev Food Sci Nutr. 2024: 1–29.

[81] Hou H, Chen D, Zhang K, et al. Gut microbiota-derived short-chain fatty acids and colorectal cancer: ready for clinical translation?. Cancer Lett. 2022; 526: 225–235.

[82] Mirzaei R, Dehkhodaie E, Bouzari B, et al. Dual role of microbiota-derived short-chain fatty acids on host and pathogen. Biomed Pharmacother. 2022; 145: 112352.

[83] Zhu X, Li K, Liu G, et al. Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. Gut Microbes. 2023; 15(2): 2249143.

[84] He Y, Fu L, Li Y, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab. 2021; 33(5): 988–1000.

[85] Luu M, Riester Z, Baldrich A, et al. Microbial short-chain fatty acids modulate CD8(+) T cell responses and improve adoptive immunotherapy for cancer. Nat Commun. 2021; 12(1): 4077.

[86] Kang X, Lau H, Yu J. Modulating gut microbiome in cancer immunotherapy: harnessing microbes to enhance treatment efficacy. Cell Rep Med. 2024; 5(4): 101478.

[87] Kim C. Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity. Cell Mol Immunol. 2023; 20(4): 341–350.

[88] Villemin C, Six A, Neville BA, Lawley TD, Robinson MJ, Bakdash G. The heightened importance of the microbiome in cancer immunotherapy. Trends Immunol. 2023; 44(1): 44–59.

[89] Donohoe D, Holley D, Collins LB, et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov. 2014; 4(12): 1387–1397.

[90] Yang K, Hou Y, Zhang Y, et al. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021; 218(3): e20201915.

[91] Uribe-Herranz M, Rafail S, Beghi S, et al. Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J Clin Invest. 2020; 130(1): 466–479.

[92] Reyes-Hernández O, Figueroa-González G, Quintas-Granados LI, et al. 3, 3′-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways. Cancer Cell Int. 2023; 23(1): 180.

[93] Teng H, Wang Y, Sui X, et al. Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer. Cancer Cell. 2023; 41(1): 124–138.

[94] Zhou H, Wang L, Lin Z, et al. Methylglyoxal from gut microbes boosts radiosensitivity and radioimmunotherapy in rectal cancer by triggering endoplasmic reticulum stress and cGAS-STING activation. J Immunother Cancer. 2023; 11(11).

[95] Song Q, Zhang X, Liu W, et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol. 2023; 79(6): 1352–1365.

[96] Liu L, Yang J, Wei Q. IDDF2023-ABS-0240 High-fat diet promotes radiation resistance in rectal cancer through inducing gut dysbiosis and increasing bile acid metabolites. BMJ Publishing Group; 2023.

[97] Tu Y, Luo L, Zhou Q, Ni J, Tang Q. Fecal microbiota transplantation repairs radiation enteritis through modulating the gut microbiota-mediated tryptophan metabolism. Radiat Res. 2024; 201(6): 572–585.

[98] Then C, Paillas S, Moomin A, et al. Dietary fibre supplementation enhances radiotherapy tumour control and alleviates intestinal radiation toxicity. Microbiome. 2024; 12(1): 89.

[99] Spencer C, McQuade JL, Gopalakrishnan V, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021; 374(6575): 1632–1640.

[100] Wang L, Lynch C, Pitroda SP, et al. Radiotherapy and immunology. J Exp Med. 2024; 221(7): e20232101.

[101] Wong K, Johnson D, Hui EP, Lam RC, Ma BB, Chan AT. Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers. Cancer Treat Rev. 2022; 105: 102361.

[102] Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022; 7(1): 258.

[103] Fang J, Lu Y, Zheng J, et al. Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications. Cell Death Dis. 2023; 14(9): 586.

[104] Seo E, Lee S, Son Y. Multifaceted functions of tissue-resident memory T cells in tumorigenesis and cancer immunotherapy. Cancer Immunol, Immunother. 2025; 74(6): 184.

[105] Ramanan D, Pratama A, Zhu Y, et al. Regulatory T cells in the face of the intestinal microbiota. Nat Rev Immunol. 2023; 23(11): 749–762.

[106] Kang J, Zappasodi R. Modulating Treg stability to improve cancer immunotherapy. Trends Cancer. 2023; 9(11): 911–927.

[107] Overacre-Delgoffe A, Bumgarner HJ, Cillo AR, et al. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity. 2021; 54(12): 2812-2824. e4.

[108] Li S, Chen K, Sun Z, et al. Radiation drives tertiary lymphoid structures to reshape TME for synergized antitumour immunity. Expert Rev Mol Med. 2024; 26: e30.

[109] Wang H, You W, Zhu Z, et al. Streptococcus lutetiensis inhibits CD8+ IL17A+ TRM cells and leads to gastric cancer progression and poor prognosis. NPJ Precis Oncol. 2025; 9(1): 43.

[110] Chen J, Levy A, Tian A, et al. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer Cell. 2025; 43(3): 361-379. e10.

[111] De Visser K, Joyce J. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023; 41(3): 374–403.

[112] Westerterp M, Gautier EL, Ganda A, et al. Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity. Cell Metabolism. 2017; 25(6): 1294-1304. e6.

[113] Déjean G, Tudela H, Bruno L, Kissi D, Rawadi G, Claus SP. Identifying a novel bile salt hydrolase from the keystone gut bacterium Christensenella minuta. Microorganisms. 2021; 9(6): 1252.

[114] Overacre-Delgoffe A, Hand T. Regulation of tissue-resident memory T cells by the microbiota. Mucosal Immunol. 2022; 15(3): 408–417.

[115] Bender M, McPherson AC, Phelps CM, et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell. 2023; 186(9): 1846-1862. e26.

[116] Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy—current perspectives and future directions. Cell. 2023; 186(8): 1652–1669.

[117] Fernandes D, Andreyev J. Pelvic radiation disease and the gastrointestinal tract, in Intestinal failure. Springer; 2023: 269–287.

[118] Tirado F, Bhanja P, Castro-Nallar E, Olea XD, Salamanca C, Saha S. Radiation-induced toxicity in rectal epithelial stem cell contributes to acute radiation injury in rectum. Stem Cell Res Ther. 2021; 12(1): 63.

[119] Lam S, Peppelenbosch M, Fuhler G. Prediction and treatment of radiation enteropathy: can intestinal bugs lead the way?. Clin Cancer Res. 2019; 25(21): 6280–6282.

[120] Xin J, Wang J, Ding Q, et al. Potential role of gut microbiota and its metabolites in radiation-induced intestinal damage. Ecotoxicol Env Safety. 2022; 248: 114341.

[121] Park H, Yu J. X-ray radiation-induced intestinal barrier dysfunction in human epithelial Caco-2 cell monolayers. Ecotoxicol Env Safety. 2023; 264: 115404.

[122] Devarakonda S, Thorsell A, Hedenström P, et al. Low-grade intestinal inflammation two decades after pelvic radiotherapy. EBioMedicine. 2023; 94.

[123] Hao W, Hao C, Wu C, Xu Y, Jin C. Aluminum induced intestinal dysfunction via mechanical, immune, chemical and biological barriers. Chemosphere. 2022; 288: 132556.

[124] Xie L, Lu H, Tang L, et al. probiotic consortia protect the intestine against radiation injury by improving intestinal epithelial homeostasis. Int J Radiat Oncol Biol Phys. 2024; 120(1): 189–204.

[125] Wang Z, Wang Q, Wang X, et al. Gut microbial dysbiosis is associated with development and progression of radiation enteritis during pelvic radiotherapy. J Cell Mol Med. 2019; 23(5): 3747–3756.

[126] Epperly M, Yu J, van Pijkeren J, et al. Specific taxa of the intestinal microbiome mitigate the radiation-induced gastrointestinal syndrome. Int J Radiat Oncol Biol Phys. 2020; 108(3): S92.

[127] Yi Y, Lu W, Shen L, Wu Y, Zhang Z. The gut microbiota as a booster for radiotherapy: novel insights into radio-protection and radiation injury. Exp Hematol Oncol. 2023; 12(1): 48.

[128] Song Q, Li X, Li Q, et al. Bifidobacterium animalis suppresses non-small cell lung cancer progression and modulates tumor immunity through indole-3-acetic acid. Cell Rep, 2025. 44(8): 116132.

[129] Xie L, Lu H, Li M, Tian Y, et al. Probiotic consortia and their metabolites protect intestine against radiation injury by improving intestinal epithelial homeostasis. Int J Radiat Oncol Biol Phys. 2023; 117(2): e269.

[130] Zheng C, Niu M, Kong Y, et al. Oral administration of probiotic spore ghosts for efficient attenuation of radiation-induced intestinal injury. J Nanobiotechnol. 2024; 22(1): 303.

[131] Zhou Q, Shen B, Huang R, et al. Bacteroides fragilis strain ZY-312 promotes intestinal barrier integrity via upregulating the STAT3 pathway in a radiation-induced intestinal injury mouse model. Front Nutrit. 2022; 9: 1063699.

[132] Zhang Y, Huang R, Jiang Y, et al. The role of bacteria and its derived biomaterials in cancer radiotherapy. Acta Pharmaceutica Sinica B. 2023; 13(10): 4149–4171.

[133] Si W, Liang H, Bugno J, et al. Lactobacillus rhamnosus GG induces cGAS/STING-dependent type I interferon and improves response to immune checkpoint blockade. Gut. 2022; 71(3): 521–533.

[134] Li Y, Xiao H, Dong J, et al. Gut microbiota metabolite fights against dietary polysorbate 80-aggravated radiation enteritis. Front Microbiol. 2020; 11: 1450.

[135] Eaton S, Kaczmarek J, Mahmood D, et al. Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients. Br J Cancer. 2022; 127(12): 2087–2098.

[136] Ye S, Shah BR, Li J, et al. A critical review on interplay between dietary fibers and gut microbiota. Trends Food Sci Technol. 2022; 124: 237–249.

[137] Ji K, Zhang M, Du L, et al. Exploring the role of inulin in targeting the gut microbiota: an innovative strategy for alleviating colonic fibrosis induced by irradiation. J Agr Food Chem. 2024; 72(11): 5710–5724.

[138] Then C, Paillas S, Wang X, Hampson A, Kiltie AE. Association of Bacteroides acidifaciens relative abundance with high-fibre diet-associated radiosensitisation. BMC Biol. 2020; 18: 1–16.

[139] Liu D, Zhuang B, Wei M, et al. Oral konjac glucomannan for prevention of ionizing radiation-induced injury by regulating gut microbiota and increasing short chain fatty acids. Int J Biol Macromol. 2023; 240: 124402.

[140] Yang J, Chen S, Wu Y, Liao Y, Yen G, et al. Ameliorative effect of buckwheat polysaccharides on colitis via regulation of the gut microbiota. Int J Biol Macromol. 2023; 227: 872–883.

[141] Yan J, Chen D, Ye Z, et al. Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer. Mol Cancer. 2024; 23(1): 241.

[142] Xie L, Cai S, Lu H, et al. Microbiota-derived I3A protects the intestine against radiation injury by activating AhR/IL-10/Wnt signaling and enhancing the abundance of probiotics. Gut Microbes. 2024; 16(1): 2347722.

[143] Xiao H, Cui M, Li Y, et al. Gut microbiota-derived indole 3-propionic acid protects against radiation toxicity via retaining acyl-CoA-binding protein. Microbiome. 2020; 8(1): 69.

[144] Cui M, Xiao H, Luo D, et al. circadian rhythm shapes the gut microbiota affecting host radiosensitivity. Int J Mol Sci. 2016; 17(11).

[145] Li M, Gu M, Lang Y, et al. The vanillin derivative VND3207 protects intestine against radiation injury by modulating p53/NOXA signaling pathway and restoring the balance of gut microbiota. Free Radic Biol Med. 2019; 145: 223–236.

[146] Duan X, Cai H, Hu T, et al. Ginsenoside Rg3 treats acute radiation proctitis through the TLR4/MyD88/NF-κB pathway and regulation of intestinal flora. Front Cell Infect Microbiol. 2023; 12: 1028576.

[147] Cosar R, Ozen A, Tastekin E, et al. Does gender difference effect radiation-induced lung toxicity? An experimental study by genetic and histopathological predictors. Rad Res. 2022; 197(3): 280–288.

[148] Andruska N, Schlaak RA, Frei A, et al. Differences in radiation-induced heart dysfunction in male versus female rats. Int J Rad Biol. 2023; 99(7): 1096–1108.

[149] Taliaferro L, Agarwal RK, Coleman CN, et al. Sex differences in radiation research. Taylor & Francis; 2024.

[150] Wang Z, Xiao H, Dong J, et al. Sexual dimorphism in gut microbiota dictates therapeutic efficacy of intravenous immunoglobulin on radiotherapy complications. J Adv Res. 2023; 46: 123–133.

[151] Li Y, Dong J, Xiao H, et al. Caloric restriction alleviates radiation injuries in a sex-dependent fashion. FASEB J. 2021; 35(8): e21787.

[152] Saxami G, Kerezoudi E, Eliopoulos C, Arapoglou D, Kyriacou A, et al. The gut–organ axis within the human body: gut dysbiosis and the role of prebiotics. Life. 2023; 13(10): 2023.

[153] Rzepecki A, Birnbaum M, Ohri N, et al. Characterizing the effects of radiation dermatitis on quality of life: a prospective survey-based study. J Am Acad Dermatol. 2022; 86(1): 161–163.

[154] Feng Z, Zhang Y, Yang C, et al. Bioinspired and inflammation-modulatory glycopeptide hydrogels for radiation-induced chronic skin injury repair. Adv Healthcare Mater. 2023; 12(1): 2201671.

[155] Trompette A, Pernot J, Perdijk O, et al. Gut-derived short-chain fatty acids modulate skin barrier integrity by promoting keratinocyte metabolism and differentiation. Muc Immunol. 2022; 15(5): 908–926.

[156] Mahmud M, Akter S, Tamanna SK, et al. Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases. Gut Microbes. 2022; 14(1): 2096995.

[157] Xiao X, Hu X, Yao J, et al. The role of short-chain fatty acids in inflammatory skin diseases. Front Microbiol. 2023; 13: 1083432.

[158] Luo N, Zhu W, Li X, et al. Defective autophagy of pericytes enhances radiation-induced senescence promoting radiation brain injury. Neuro-Oncology. 2024; 26(12): 2288–2304.

[159] Loh J, Mak WQ, Tan LKS, et al. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther. 2024; 9(1): 37.

[160] Hu J, Wang C, Li Q, et al. Lycium barbarum polysaccharide ameliorates radiation-induced brain injury by regulating gut microbiota. J Trad Chinese Med Sci. 2023; 10(1): 42–51.

[161] Hu J, Jiao W, Tang Z, et al. Quercetin inclusion complex gels ameliorate radiation-induced brain injury by regulating gut microbiota. Biomed Pharmacother. 2023; 158: 114142.

[162] Zhang Y, Hu J, Song X, et al. The effects of Lactobacillus reuteri microcapsules on radiation-induced brain injury by regulating the gut microenvironment. Food Funct. 2023; 14(22): 10041–10051.

[163] Venkidesh B, Shankar SR, Narasimhamurthy RK, Rao SBS, Mumbrekar KD. Radioprotective potential of probiotics against gastrointestinal and neuronal toxicity: a preclinical study. Clin Transl Oncol. 2023; 25(11): 3165–3173.

[164] Iovoli A, Turecki L, Qiu ML, et al. Severe oral mucositis after intensity-modulated radiation therapy for head and neck cancer. JAMA Network Open. 2023; 6(10): e2337265–e2337265.

[165] Xiao X, Zhang X, Wang J, et al. Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study. Gut. 2024; 73(7): 1098–1109.

[166] Al-Qadami G, Verma G, Van Sebille Y, et al. Antibiotic-induced gut microbiota depletion accelerates the recovery of radiation-induced oral mucositis in rats. Int J Rad Oncol Biol Phys. 2022; 113(4): 845–858.

[167] Kunath B, De Rudder C, Laczny CC, Letellier E, Wilmes P. The oral–gut microbiome axis in health and disease. Nat Rev Microbiol. 2024; 22: 1–15.

[168] Perdijk O, Azzoni R, Marsland B. The microbiome: an integral player in immune homeostasis and inflammation in the respiratory tract. Physiol Rev. 2024; 104(2): 835–879.

[169] Zhou X, Xue J, Zhao Q. Short chain fatty acids for prevention and treatment of radiation lung injury. Int J Rad Oncol Biol Phys. 2024; 120(2): e422.

[170] Li Z, Shen Y, Xin J, et al. Cryptotanshinone alleviates radiation-induced lung fibrosis via modulation of gut microbiota and bile acid metabolism. Phytother Res. 2023; 37(10): 4557–4571.

[171] Chen Z, Wang B, Dong J, et al. Gut microbiota-derived l-histidine/imidazole propionate axis fights against the radiation-induced cardiopulmonary injury. Int J Mol Sci. 2021; 22(21): 11436.

[172] Tsai C, Cheng JC, Wang K, Wang AZ, Tepper JE. Hepatobiliary Malignancies, in Hypofractionated and stereotactic radiation therapy: a practical guide. Springer; 2024: 375–392.

[173] Song Q, Zhang X. The role of gut–liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC. Biomedicines. 2022; 10(3): 524.

[174] Tilg H, Adolph T, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Met. 2022; 34(11): 1700–1718.

[175] Yan M, Man S, Sun B, et al. Gut liver brain axis in diseases: the implications for therapeutic interventions. Signal Transduct Target Ther. 2023; 8(1): 443.

[176] Miousse I, Ewing LE, Skinner CM, et al. Methionine dietary supplementation potentiates ionizing radiation-induced gastrointestinal syndrome. Am J Physiol-Gastrointest Liver Physiol. 2020; 318(3): G439–G450.

[177] Wang W, Cui B, Nie Y, Sun L, Zhang F. Radiation injury and gut microbiota-based treatment. Protein Cell. 2024; 15(2): 83–97.

[178] Zhang Y, Chen X, Wang X, et al. Insights into ionizing radiation-induced bone marrow hematopoietic stem cell injury. Stem Cell Res Ther. 2024; 15(1): 222.

[179] Zeng X, Li X, Li X, et al. Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation. Blood. 2023; 141(14): 1691–1707.

[180] Guan D, Yang Y, Pang M, et al. Indole-3-carboxaldehyde ameliorates ionizing radiation-induced hematopoietic injury by enhancing hematopoietic stem and progenitor cell quiescence. Mol Cell Biochem. 2024; 479(2): 313–323.

[181] Zhang Y, Wu Y, Liu X, Chen X, Su J. Targeting the gut microbiota-related metabolites for osteoporosis: the inextricable connection of gut-bone axis. Age Res Rev. 2024: 102196.

[182] Chen Y, Jin E, Day P. Use of drug sensitisers to improve therapeutic index in cancer. Pharmaceutics. 2024; 16(7): 928.

[183] Sims T, El Alam MB, Karpinets TV, et al. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol. 2021; 4(1): 237.

[184] Sasaki T, Matsumoto Y, Murakami K, et al. Gut microbiome can predict chemoradiotherapy efficacy in patients with esophageal squamous cell carcinoma. Esophagus. 2023; 20(4): 691–703.

[185] Huo R, Wang Y, Hou S, Wang W, Zhang C, Wan X. Gut mucosal microbiota profiles linked to colorectal cancer recurrence. World J Gastroenterol. 2022; 28(18): 1946–1964.

[186] Cheng M, Jin M, Yang S, et al. Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study. J Immunother Cancer. 2025; 13(1): e009415.

[187] Al-Qadami G. Exploring the role of the gut microbiome in toxicity and response to radiotherapy for head and neck cancer. University of Adelaide, School of Biomedicine; 2021.

[188] Iacovacci J, Serafini MS, Avuzzi B, et al. Intestinal microbiota composition is predictive of radiotherapy-induced acute gastrointestinal toxicity in prostate cancer patients. Ebiomedicine. 2024; 106: 105246.

[189] Bai J, Barandouzi ZA, Rowcliffe C, Meador R, Tsementzi D, Bruner DW. Gut microbiome and its associations with acute and chronic gastrointestinal toxicities in cancer patients with pelvic radiation therapy: a systematic review. Front Oncol. 2021; 11: 745262.

[190] Cai S, Yang Y, Kong Y, et al. Gut bacteria Erysipelatoclostridium and its related metabolite ptilosteroid a could predict radiation-induced intestinal injury. Front Public Health. 2022; 10: 862598.

[191] Ciernikova S, Sevcikova A, Drgona L, Mego M. Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: an emerging trend in cancer patient care. Biochimica et Biophysica Acta (BBA)-Rev Cancer. 2023: 188990.

[192] Geiger M. Study of the effect of faecal microbiota transfer (FMT) therapy on a preclinical radiation-induced colorectal model. Sorbonne Université; 2023.

[193] Jian Y, Yang G, Zhang L, et al. Lactobacillus plantarum alleviates irradiation-induced intestinal injury by activation of FXR-FGF15 signaling in intestinal epithelia. Journal of Cellular Physiology. 2022; 237(3): 1845–1856.

[194] Goel V, et al. Radiation enteritis in patients receiving abdominal radiation therapy, in complications of cancer therapy: best practices in prevention and management. Springer; 2024: 25–35.

[195] Giridhar P, Pradhan S, Dokania S, Venkatesulu B, Sarode R, Welsh JS. Microbiome and abdominopelvic radiotherapy related chronic enteritis: a microbiome-based mechanistic role of probiotics and antibiotics. Am J Clin Oncol. 2024; 47(5): 246–252.

[196] Wang L, Li Y, Zhang Y, Peng L. Intestinal microecological transplantation for a patient with chronic radiation enteritis: a case report. World J Gastroenterol. 2024; 30(19): 2603–2611.

[197] Linn Y, Thu K, Win N. Effect of probiotics for the prevention of acute radiation-induced diarrhoea among cervical cancer patients: a randomized double-blind placebo-controlled study. Probiotics Antimicrob Proteins. 2019; 11: 638–647.

[198] Guo J, Zhang H, Lu X, Xia L. Viable Bifidobacterium tablets for the prevention of chemotherapy-/radiation-induced mucositis in patients undergoing haematopoietic stem cell transplantation. Supportive Care in Cancer. 2023; 31(5): 282.

[199] Ahrén I, Bjurberg M, Steineck G, Bergmark K, Jeppsson B. Decreasing the adverse effects in pelvic radiation therapy: a randomized controlled trial evaluating the use of probiotics. Adv Radiat Oncol. 2023; 8(1): 101089.

[200] Zhang Q, Kuang G, Li W, Wang J, Ren H, Zhao Y. Stimuli-responsive gene delivery nanocarriers for cancer therapy. Nano-Micro Lett. 2023; 15(1): 44.

[201] Shi L, Lv H, Chen C, et al. Regulation of gut microbiome with redox responsible bacterial cellulose hydrogel for precision chemo-radiotherapy of intestinal cancer. Chem Eng J. 2022; 446: 137340.

[202] Zhang D, Zhong D, Ouyang J, et al. Microalgae-based oral microcarriers for gut microbiota homeostasis and intestinal protection in cancer radiotherapy. Nat Commun. 2022; 13(1): 1413.

[203] Gurbatri C, Arpaia N, Danino T. Engineering bacteria as interactive cancer therapies. Science. 2022; 378(6622): 858–864.

[204] Wang W, Xu H, Ye Q, et al. Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria. Nat Biomed Eng. 2022; 6(1): 44–53.

[205] Zhang Y, Liu Y, Li T, et al. Engineered bacteria breach tumor physical barriers to enhance radio-immunotherapy. J Control Release. 2024; 373: 867–878.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.